Icosavax buy­out caps As­traZeneca’s long search for a vac­cine plat­form

As­traZeneca is gain­ing a late-stage RSV vac­cine can­di­date as part of its pro­posed ac­qui­si­tion of Icosavax af­ter the British drug­mak­er spent two years search­ing for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER